Wide Ranks

MNOV

MediciNova, Inc.

2.01

Top Statistics
Market Cap 98 M Forward PE -0.0551 Revenue Growth 0.00 %
Current Ratio 18.24 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -4.66 Enterprise / Revenue 45.66 Price To Sales Trailing12 Months 98.58
Profitability
Profit Margins 0.00 % Operating Margins -981.95 %
Balance Sheet
Total Cash 44 M Total Cash Per Share 0.9040 Total Debt 492530
Total Debt To Equity 0.8580 Current Ratio 18.24 Book Value Per Share 1.27
All Measures
Short Ratio 1120.00 % Message Board Id finmb_9262264 Fax 858 404 0048
Shares Short Prior Month 196805 Return On Equity -0.1332 City La Jolla
Uuid c2932104-58fe-3a03-8298-c9f1617dc654 Previous Close 2.08 First Trade Date Epoch Utc 1 B
Book Value 1.27 Beta 0.7690 Total Debt 492530
Volume 50296 Price To Book 1.58 Fifty Two Week Low 1.12
Total Cash Per Share 0.9040 Total Revenue 1000000 Shares Short Previous Month Date 1 B
Target Median Price 8.00 Audit Risk 8 Max Age 86400
Recommendation Mean 1.00 Sand P52 Week Change 0.3133 Operating Margins -981.95 %
Target Mean Price 8.00 Net Income To Common -8164910 Short Percent Of Float 0.0043
Implied Shares Outstanding 49 M Trailing Peg Ratio None Last Fiscal Year End 1 B
Average Daily Volume10 Day 62370 Average Volume10days 62370 Total Cash 44 M
Next Fiscal Year End 1 B Revenue Per Share 0.0200 Held Percent Insiders 0.0298
Trailing PE 0.0000 Date Short Interest 1 B Most Recent Quarter 1 B
Share Holder Rights Risk 5 Regular Market Previous Close 2.08 Target Low Price 6.00
Gmt Off Set Milliseconds -18000000 Fifty Day Average 1.85 Open 2.08
Free Cashflow -6552178 State CA Dividend Yield 0.00 %
Return On Assets -0.0951 Time Zone Short Name EST Board Risk 8
Trailing Eps -0.2100 Day Low 2.00 Address1 4275 Executive Square
Shares Outstanding 49 M Compensation Risk 7 Price Hint 4
Target High Price 10.00 Website https://www.medicinova.com 52 Week Change 0.1105
Average Volume 80357 Forward Eps -36.49 Recommendation Key strong_buy
Compensation As Of Epoch Date 1 B Quick Ratio 1777.50 % Is_sp_500 False
Regular Market Day High 2.08 Profit Margins 0.00 % Debt To Equity 0.8580
Fifty Two Week High 2.55 Day High 2.08 Shares Short 182203
Regular Market Open 2.08 Industry Key biotechnology Earnings Growth 0.00 %
Enterprise To Revenue 45.66 Revenue Growth 0.00 % Shares Percent Shares Out 0.0037
Operating Cashflow -8549787 Currency USD Time Zone Full Name America/New_York
Market Cap 98 M Is_nasdaq_100 False Zip 92037
Quote Type EQUITY Industry Biotechnology Long Name MediciNova, Inc.
Overall Risk 7 Regular Market Day Low 2.00 Held Percent Institutions 0.2130
Current Price 2.01 Address2 Suite 300 Enterprise To Ebitda -4.66
Financial Currency USD Current Ratio 18.24 Gross Margins 100.00 %
Industry Disp Biotechnology Number Of Analyst Opinions 2 Country United States
Float Shares 42 M Two Hundred Day Average 1.51 Governance Epoch Date 1 B
Enterprise Value 45 M Price To Sales Trailing12 Months 98.58 Forward PE -0.0551
Regular Market Volume 50296 Ebitda -9797566 Exchange NGM
Go to Yahoo Finance Go to Seeking Alpha 
MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States.

It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID.

The company's product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic and other diseases, including nonalcoholic fatty liver disease and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers.

It has license agreements with Kyorin Pharmaceutical Co.

, Ltd; Angiogene Pharmaceuticals, Ltd.

; and Meiji Seika Kaisha, Ltd.

The company was incorporated in 2000 and is headquartered in La Jolla, California.